<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Voriconazole: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i948.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i948.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i948.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i288.htm">Antifungals</a> &gt; <a href="41001i300.htm">Antifungals, Triazole</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1060.htm" title="Previous: Posaconazole">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i301.htm" title="Next: Fluconazole">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i948">Voriconazole</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Voriconazole</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i86.htm" name="_86">Alfentanil</a></td><td class="cBV"><b> voriconazole increases plasma concentration of alfentanil (consider reducing dose of alfentanil)</b></td><td></td></tr><tr><td><a href="41001i1217.htm" name="_1217">Apixaban</a></td><td>avoidance of  voriconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1204.htm" name="_1204">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> voriconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i865.htm" name="_865">Clopidogrel</a></td><td class="cBV"><b> voriconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> voriconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td class="cBV"><b> voriconazole increases plasma concentration of diazepam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i64.htm" name="_64">Diclofenac</a></td><td> voriconazole increases plasma concentration of diclofenac </td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by efavirenz , also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose)</b></td><td></td></tr><tr><td><a href="41001i914.htm" name="_914">Esomeprazole</a></td><td> voriconazole possibly increases plasma concentration of esomeprazole </td><td></td></tr><tr><td><a href="41001i1169.htm" name="_1169">Everolimus</a></td><td class="cBV"><b> voriconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i783.htm" name="_783">Ibuprofen</a></td><td> voriconazole increases plasma concentration of ibuprofen </td><td></td></tr><tr><td><a href="41001i1128.htm" name="_1128">Lapatinib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td class="cBV"><b> voriconazole increases plasma concentration of methadone (consider reducing dose of methadone)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> voriconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i1118.htm" name="_1118">Nilotinib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  voriconazole increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm" name="_752">Omeprazole</a></td><td> voriconazole increases plasma concentration of omeprazole (consider reducing dose of omeprazole)</td><td></td></tr><tr><td><a href="41001i901.htm" name="_901">Oxycodone</a></td><td class="cBV"><b> voriconazole increases plasma concentration of oxycodone </b></td><td></td></tr><tr><td><a href="41001i1186.htm" name="_1186">Pazopanib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly reduced by phenobarbital—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> voriconazole increases plasma concentration of phenytoin , also phenytoin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for phenytoin toxicity)</b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>plasma concentration of  voriconazole possibly increased by progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b> voriconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> voriconazole increases plasma concentration of rifabutin , also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by ritonavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm" name="_1136">Rivaroxaban</a></td><td>avoidance of  voriconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td>possible increased risk of myopathy when  voriconazole given with simvastatin </td><td></td></tr><tr><td><a href="41001i921.htm" name="_921">Sirolimus</a></td><td class="cBV"><b> voriconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i268.htm" name="_268">Sulfonylureas</a></td><td> voriconazole possibly increases plasma concentration of sulfonylureas </td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> voriconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly affected by telaprevir (possible increased risk of ventricular arrhythmias)</b></td><td></td></tr></tbody></table><p>Voriconazole belongs to <b>Antifungals, Triazole</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i290.htm">Amphotericin</a></td><td> triazoles possibly antagonise effects of amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  triazoles advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  triazoles given with atorvastatin </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  triazoles given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of fentanyl </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  triazoles given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>avoidance of  triazoles advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> triazoles possibly increase plasma concentration of saquinavir </td><td></td></tr></tbody></table><p>Voriconazole belongs to <b>Antifungals</b>
          but <b>Antifungals</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1060.htm">Previous: Posaconazole</a> | <a class="top" href="41001i948.htm#">Top</a> | <a accesskey="]" href="41001i301.htm">Next: Fluconazole</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>